Feature | July 19, 2013

Mount Sinai Medical Center First in New York to Offer HeartMate II Pocket Controller

July 19, 2013 — The Mount Sinai Medical Center is the first medical center in New York City to offer the HeartMate II pocket controller, newly approved by the U.S. Food and Drug Administration (FDA), to help its advanced heart failure patients maintain more active lifestyles. This latest-generation controller for the HeartMate II left ventricular assist device (LVAD) is a new small, lightweight, patient-friendly external controller about the size of a smart phone that easily fits in a patient’s front pocket and powers their heart to pump.

“This new HeartMate II controller is a good step forward for our heart failure patients who are awaiting a heart transplant or in need of long-term, permanent support for their survival,” says Sean P. Pinney, M.D., director of the Advanced Heart Failure & Cardiac Transplantation Program at Mount Sinai. “With its smaller size and intuitive safety features, we expect the new controller will enhance the daily lives of our heart failure patients.”

Mount Sinai has one of the largest LVAD programs in the United States, with its cardiothoracic surgeons implanting approximately 50 each year. The center started using LVAD technology in 2006 for advanced heart failure patients. It is used as a bridge-to-transplant (BTT) therapy or destination therapy (DT) for permanent support. In addition, Mount Sinai performs dozens of successful heart transplants each year.

“This new controller will improve the LVAD patient’s overall experience [and] heighten the quality of their life by supporting their active lifestyle, while providing pocket-sized peace of mind for them and their clinical care team,” says Kimberly Ashley, FNP-BC, the VAD program manager for the Advanced Heart Failure & Cardiac Transplantation Program. “We hope to expand the use of this pocket-sized HeartMate II controller to not only new patients but also those current HeartMate II users to give them the option to swap out their old controller for the smaller, safer version, making their lives more comfortable and normal during their daily activities.”

The new patient-friendly controller is a small computer attached to the HeartMate II LVAD via one side cable. It enhances patients’ safety by powering their LVAD to pump their heart, monitoring their vital signs and alerting them of any concerns. Its new design features a diagnostic check system to make sure device wires are intact and functional, special visual alarms, precise onscreen instructions for the patient and longer backup battery power. In addition, the device is programmed with 37 languages to serve diverse patient populations.

“We do extensive patient education training before and after LVAD surgery to teach patients exactly how their controllers work, how to closely monitor their LVAD’s status and also to be vitally aware of any issues or concerns that may arise,” says Bess Griffin, RN, BSN, the VAD coordinator for the Advanced Heart Failure & Cardiac Transplantation Program. “The staff — who have begun training on the new, smart, smaller controller — really enjoy the device’s very easy, user-friendly interface. Thanks to the new controller we are expecting patients may be trained more quickly and feel more confident in caring for their device at home.”

The pocket controller is available for new advanced heart failure patients in need who receive HeartMate II, as well as for current HeartMate II patients who wish to upgrade their existing system controllers.

For more information: www.mountsinai.org

Related Content

CardioKinetix, Parachute device, heart failure, 500th implantation, PARACHUTE IV Trial
News | Heart Failure| July 22, 2016
CardioKinetix Inc. announced this week that 500 patients have received the company’s Parachute Ventricular Partitioning...
University of Guelph study, heart failure risk, gender, aging
News | Heart Failure| July 08, 2016
University of Guelph researchers have uncovered a possible clue as to why women have lower rates of heart failure than...
SynCardia acquired, Versa Capital Management, chapter 11
News | Business| July 07, 2016
SynCardia Systems Inc. announced that it has entered into an asset purchase agreement (“APA”) with an affiliate of...
News | Heart Failure| July 05, 2016
A research team has developed a new electric mesh device that can be wrapped around the heart to deliver electrical...
HeartWare, HVAD, batteries recall
News | Ventricular Assist Devices (VAD)| July 05, 2016
HeartWare Inc. announced a recall of the batteries used on the HeartWare Ventricular Assist Device (HVAD) because the...
beta-blockers, Thomas Jefferson University, beta-adrenergic receptors

Selective activation of the beta2-adrenergic receptor (beta2AR) by a beta-arrestin-biased pepducin promotes activation of a beta-arrestin signaling pathway that is cardioprotective. Image courtesy of the lab of Jeffrey Benovic, Thomas Jefferson University.

News | Heart Failure| June 30, 2016
Researchers at Thomas Jefferson University have discovered how to enhance the effectiveness of beta-blockers for heart...
Sponsored Content | Videos | Cardio-oncology| June 30, 2016
Interview with Federico Asch, M.D., FACC, FASE, associate director of the echocardiography core lab at Medstar Health
St. Jude Medical, HeartMate 3 LVAS, LVAD, CardioStim-EHRA Europace Innovation Award 2016
News | Ventricular Assist Devices (VAD)| June 29, 2016
St. Jude Medical Inc. recently announced the company received an Innovation Award for its HeartMate 3 Left Ventricular...
St. Jude Medical, CE Mark, SyncAV CRT, MultiPoint Pacing, CardioStim 2016
Technology | Cardiac Resynchronization Therapy Devices (CRT)| June 28, 2016
St. Jude Medical Inc. announced CE Mark approval and launch of SyncAV CRT software, designed to build upon the company’...
Overlay Init